 | • レポートコード：TPM-JL052 • 出版社/出版日：Transparency Market Research / 2019年5月14日 • レポート形態：英文、PDF、220ページ • 納品方法：Eメール • 産業分類：医薬品 |
| Single User | ￥857,660 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,301,660 (USD8,795) | ▷ お問い合わせ |
| Global Site License | ￥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本資料は、心停止治療の世界市場について調べ、心停止治療の世界市場規模、市場動向、市場シェア、市場環境、市場予測、治療別（薬及び医療機器）分析、販売チャネル別（病院、独立系薬局）分析、関連企業情報などをまとめました。 ・心停止治療の市場概要 ・心停止治療の市場動向 ・心停止治療の世界市場規模・予測 ・心停止治療市場：治療別（薬及び医療機器） ・心停止治療市場：販売チャネル別（病院、独立系薬局） ・地域別分析（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米） ・競争環境・関連企業分析 |
Cardiac Arrest Treatment Market – Overview
This report analyzes the current and future scenario of the global cardiac arrest treatment market. Cardiac resynchronization therapy (CRT) has been considered the standard and most effective form of first aid in case of a sudden cardiac arrest and has been taught in classrooms and community centers across the world. Despite such popularity and awareness, CRT alone cannot save sudden cardiac arrest (SCA) victims. Majority of the people who experience sudden cardiac arrest have ventricular fibrillation (VF) which causes the heart muscles to beat rapidly and improperly in which CRT alone cannot provide effective results. The global cardiac arrest treatment market is driven by rise in chronic heart health conditions, increase in geriatric and overall population with cardiovascular disorders.
The global cardiac arrest treatment market report comprises an elaborate executive summary, which includes a market snapshot that provides information about various segments of the market. It also provides information and data analysis of the global market with respect to the segments based on treatment, sales channel, and region. A detailed qualitative analysis of drivers and restraints of the market and opportunities has been provided in the overview section. Additionally, the section comprises competitive matrix and company profiles with business overview to understand the competitive landscape in the market. This section of the report also provides market attractiveness analysis by region and market share analysis by key players, thereby presenting a thorough analysis of the overall competitive scenario in the global cardiac arrest treatment market.
Global Cardiac Arrest Treatment Market: Key Segments
In terms of treatment, the global cardiac arrest treatment market has been segmented into drugs and medical devices. The drugs segment has been categorized into vasopressors, anti-arrhythmic drugs, anticholinergic drugs, corticosteroids, fibrinolytic drugs, beta blockers, and others (sodium bicarbonate, crystalloids, colloids, etc.). The medical devices segment has been classified into defibrillators, cardiac resynchronization therapy (CRT), and others. In terms of sales channel, the global cardiac arrest treatment market has been divided into hospitals, independent pharmacies, and others. The market size and forecast for each of these segments have been provided in terms of US$ Mn for the period from 2017 to 2027, along with their respective CAGRs for the forecast period from 2019 to 2027, considering 2018 as the base year.
Global Cardiac Arrest Treatment Market: Regional Outlook
Geographically, the global cardiac arrest treatment market has been segmented into five major regions: North America (the U.S. and Canada), Europe (the U.K., Germany, France, Spain, Italy, and Rest of Europe), Asia Pacific (India, China, Japan, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa (South Africa, GCC Countries, and Rest of Middle East & Africa). The market size and forecast for each of these regions and the mentioned countries/sub-regions have been provided for the period from 2017 to 2027, along with their respective CAGRs for the forecast period from 2019 to 2027, considering 2018 as the base year. The research study also covers the competitive scenario in these regions.
Companies Mentioned in Report
The report also profiles major players in the global cardiac arrest treatment market based on various attributes such as company overview, financial overview, treatment portfolio, business strategies, and recent developments. These are Amgen, Inc., Pfizer, Inc., Johnson & Johnson, Novartis AG, Bristol-Myers Squibb Company, Abbott, Bayer AG, Koninklijke Philips N.V., GE Healthcare, Physio-Control, Inc. (Stryker), Boston Scientific Corporation, Cardiac Science Corporation (Aurora Capital Group), and Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
The global cardiac arrest treatment market has been segmented as below:
Global Cardiac Arrest Treatment Market, by Treatment
Drugs
Vasopressors
Anti-arrhythmic Drugs
Anticholinergic Drugs
Corticosteroids
Fibrinolytic Drugs
Beta Blockers
Others (sodium bicarbonate, crystalloids, colloids, etc.)
Medical Devices
Defibrillators
Cardiac Resynchronization Therapy (CRT)
Others
Global Cardiac Arrest Treatment Market, by Sales Channel
Hospitals
Independent Pharmacies
Others
Global Cardiac Arrest Treatment Market, by Region
North America
U.S.
Canada
Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe
Asia Pacific
China
Japan
India
Australia & New Zealand
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East & Africa
GCC Countries
South Africa
Rest of Middle East & Africa
1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
2. Assumptions and Research Methodology
2.1. Assumptions and Acronyms Used
2.2. Research Methodology
3. Executive Summary
3.1. Global Cardiac Arrest Treatment Market Size (US$ Mn) and Distribution, by Region, 2019 and 2027
3.2. Global Cardiac Arrest Treatment Market: Market Snapshot
4. Market Overview
4.1. Global Cardiac Arrest Treatment Market: Treatment Overview
4.2. Global Cardiac Arrest Treatment Market: Key Industry Developments
4.3. Market Dynamics
4.4. Drivers and Restraints Snapshot Analysis
4.5. Drivers
4.5.1. Rise in prevalence of congestive heart failure (CHF)
4.5.2. Government initiatives
4.6. Restraints
4.6.1. Low availability of cardiac arrest treatment in emerging countries
4.6.2. Growth of the generic drugs industry
4.7. Opportunities
4.8. Global Cardiac Arrest Treatment Market Revenue Projections (US$ Mn), 2017–2027
5. Key Insights
5.1. Incidence Rate of Cardiac Arrest In Key Countries
5.2. Technological Advancements in Medical Devices for Cardiac Arrest Treatment
5.3. Treatment Usage Pattern (Three-Phase Model of Cardiac Arrest)
5.4. Promising Treatments in Clinical Development: Cardiac Arrest
5.5. Annual cost of prehospital equipment per patient used to treat OHCA (Out- of Hospital Cardiac Arrest)
5.6. Key Merger and Acquisition
5.7. Research and Development Strategies for Key Companies
5.8. Pipeline Analysis for Cardiac Arrest Therapeutics
6. Global Cardiac Arrest Treatment Market Analysis, by Treatment
6.1. Introduction
6.2. Global Cardiac Arrest Treatment Market Size and Forecast, by Treatment
6.2.1. Drugs
6.2.1.1. Vasopressors
6.2.1.2. Anti-arrhythmic Drugs
6.2.1.3. Anticholinergic Drugs
6.2.1.4. Corticosteroids
6.2.1.5. Fibrinolytic Drugs
6.2.1.6. Beta Blockers
6.2.1.7. Others (sodium bicarbonate, crystalloids, colloids, etc.)
6.2.2. Medical Devices
6.2.2.1. Defibrillators
6.2.2.2. Cardiac Resynchronization Therapy (CRT)
6.2.2.3. Others
6.3. Global Cardiac Arrest Treatment Market Analysis, by Treatment
6.4. Global Cardiac Arrest Treatment Market Attractiveness Analysis, by Treatment
7. Global Cardiac Arrest Treatment Market Analysis, by Sales Channel
7.1. Introduction
7.2. Global Cardiac Arrest Treatment Market Size and Forecast, by Sales Channel
7.2.1. Hospitals
7.2.2. Independent Pharmacies
7.2.3. Others
7.3. Global Cardiac Arrest Treatment Market Analysis, by Sales Channel
7.4. Global Cardiac Arrest Treatment Market Attractiveness Analysis, by Sales Channel
8. Global Cardiac Arrest Treatment Market Analysis, by Region
8.1. Global Cardiac Arrest Treatment Market Size and Forecast, by Region, 2017–2027
8.1.1. North America
8.1.2. Europe
8.1.3. Asia Pacific
8.1.4. Latin America
8.1.5. Middle East & Africa
8.2. Global Cardiac Arrest Treatment Market Analysis, by Region
8.3. Global Cardiac Arrest Treatment Market Attractiveness Analysis, by Region
9. North America Cardiac Arrest Treatment Market Analysis
9.1. North America Cardiac Arrest Treatment Market
9.2. North America Cardiac Arrest Treatment Market Overview
9.3. North America Cardiac Arrest Treatment Market Size and Forecast, by Treatment
9.3.1. Drugs
9.3.1.1. Vasopressors
9.3.1.2. Anti-arrhythmic Drugs
9.3.1.3. Anticholinergic Drugs
9.3.1.4. Corticosteroids
9.3.1.5. Fibrinolytic Drugs
9.3.1.6. Beta Blockers
9.3.1.7. Others (sodium bicarbonate, crystalloids, colloids, etc.)
9.3.2. Medical Devices
9.3.2.1. Defibrillators
9.3.2.2. Cardiac Resynchronization Therapy (CRT)
9.3.2.3. Others
9.4. North America Cardiac Arrest Treatment Market Size and Forecast, by Sales Channel
9.4.1. Hospitals
9.4.2. Independent Pharmacies
9.4.3. Others
9.5. North America Cardiac Arrest Treatment Market Forecast, by Country
9.5.1. U.S.
9.5.2. Canada
9.6. North America Cardiac Arrest Treatment Market Attractiveness Analysis
9.6.1. By Treatment
9.6.2. By Sales Channel
9.6.3. By Country
10. Europe Cardiac Arrest Treatment Market Analysis
10.1. Europe Cardiac Arrest Treatment Market
10.2. Europe Cardiac Arrest Treatment Market Overview
10.3. Europe Cardiac Arrest Treatment Market Size and Forecast, by Treatment
10.3.1. Drugs
10.3.1.1. Vasopressors
10.3.1.2. Anti-arrhythmic Drugs
10.3.1.3. Anticholinergic Drugs
10.3.1.4. Corticosteroids
10.3.1.5. Fibrinolytic Drugs
10.3.1.6. Beta Blockers
10.3.1.7. Others (sodium bicarbonate, crystalloids, colloids, etc.)
10.3.2. Medical Devices
10.3.2.1. Defibrillators
10.3.2.2. Cardiac Resynchronization Therapy (CRT)
10.3.2.3. Others
10.4. Europe Cardiac Arrest Treatment Market Size and Forecast, by Sales Channel
10.4.1. Hospitals
10.4.2. Independent Pharmacies
10.4.3. Others
10.5. Europe Cardiac Arrest Treatment Market Forecast, by Country/Sub-region
10.5.1. U.K.
10.5.2. France
10.5.3. Germany
10.5.4. Spain
10.5.5. Italy
10.5.6. Rest of Europe
10.6. Europe Cardiac Arrest Treatment Market Attractiveness Analysis
10.6.1. By Treatment
10.6.2. By Sales Channel
10.6.3. By Country/Sub-region
11. Asia Pacific Cardiac Arrest Treatment Market Analysis
11.1. Asia Pacific Cardiac Arrest Treatment Market Key Findings
11.2. Asia Pacific Cardiac Arrest Treatment Market Overview
11.3. Asia Pacific Cardiac Arrest Treatment Market Size and Forecast, by Treatment
11.3.1. Drugs
11.3.1.1. Vasopressors
11.3.1.2. Anti-arrhythmic Drugs
11.3.1.3. Anticholinergic Drugs
11.3.1.4. Corticosteroids
11.3.1.5. Fibrinolytic Drugs
11.3.1.6. Beta Blockers
11.3.1.7. Others (sodium bicarbonate, crystalloids, colloids, etc.)
11.3.2. Medical Devices
11.3.2.1. Defibrillators
11.3.2.2. Cardiac Resynchronization Therapy (CRT)
11.3.2.3. Others
11.4. Asia Pacific Cardiac Arrest Treatment Market Size and Forecast, by Sales Channel
11.4.1. Hospitals
11.4.2. Independent Pharmacies
11.4.3. Others
11.5. Asia Pacific Cardiac Arrest Treatment Market Forecast, by Country/Sub-region
11.5.1. China
11.5.2. India
11.5.3. Japan
11.5.4. Australia & New Zealand
11.5.5. Rest of Asia Pacific
11.6. Asia Pacific Cardiac Arrest Treatment Market Attractiveness Analysis
11.6.1. By Treatment
11.6.2. By Sales Channel
11.6.3. By Country/Sub-region
12. Latin America Cardiac Arrest Treatment Market Analysis
12.1. Latin America Cardiac Arrest Treatment Market Key Findings
12.2. Latin America Cardiac Arrest Treatment Market Overview
12.3. Latin America Cardiac Arrest Treatment Market Size and Forecast, by Treatment
12.3.1. Drugs
12.3.1.1. Vasopressors
12.3.1.2. Anti-arrhythmic Drugs
12.3.1.3. Anticholinergic Drugs
12.3.1.4. Corticosteroids
12.3.1.5. Fibrinolytic Drugs
12.3.1.6. Beta Blockers
12.3.1.7. Others (sodium bicarbonate, crystalloids, colloids, etc.)
12.3.2. Medical Devices
12.3.2.1. Defibrillators
12.3.2.2. Cardiac Resynchronization Therapy (CRT)
12.3.2.3. Others
12.4. Latin America Cardiac Arrest Treatment Market Size and Forecast, by Sales Channel
12.4.1. Hospitals
12.4.2. Independent Pharmacies
12.4.3. Others
12.5. Latin America Cardiac Arrest Treatment Market Forecast, by Country/Sub-region
12.5.1. Brazil
12.5.2. Mexico
12.5.3. Rest of Latin America
12.6. Latin America Cardiac Arrest Treatment Market Attractiveness Analysis
12.6.1. By Treatment
12.6.2. By Sales Channel
12.6.3. By Country/Sub-region
13. Middle East & Africa Cardiac Arrest Treatment Market Analysis
13.1. Middle East & Africa Cardiac Arrest Treatment Market
13.2. Middle East & Africa Cardiac Arrest Treatment Market Overview
13.3. Middle East & Africa Cardiac Arrest Treatment Market Size and Forecast, by Treatment
13.3.1. Drugs
13.3.1.1. Vasopressors
13.3.1.2. Anti-arrhythmic Drugs
13.3.1.3. Anticholinergic Drugs
13.3.1.4. Corticosteroids
13.3.1.5. Fibrinolytic Drugs
13.3.1.6. Beta Blockers
13.3.1.7. Others (sodium bicarbonate, crystalloids, colloids, etc.)
13.3.2. Medical Devices
13.3.2.1. Defibrillators
13.3.2.2. Cardiac Resynchronization Therapy (CRT)
13.3.2.3. Others
13.4. Middle East & Africa Cardiac Arrest Treatment Market Size and Forecast, by Sales Channel
13.4.1. Hospitals
13.4.2. Independent Pharmacies
13.4.3. Others
13.5. Middle East & Africa Cardiac Arrest Treatment Market Forecast, by Country/Sub-region
13.5.1. GCC Countries
13.5.2. South Africa
13.5.3. Rest of Middle East & Africa
13.6. Middle East & Africa Cardiac Arrest Treatment Market Attractiveness Analysis
13.6.1. By Treatment
13.6.2. By Sales Channel
13.6.3. By Country/Sub-region
14. Competition Landscape
14.1. Company Profiles
14.1.1. Amgen, Inc.
14.1.1.1. Overview (HQ, Employee Strength, Business Segments)
14.1.1.2. Financials
14.1.1.3. Recent Developments
14.1.1.4. Strategy
14.1.2. Pfizer, Inc.
14.1.2.1. Overview (HQ, Employee Strength, Business Segments)
14.1.2.2. Financials
14.1.2.3. Recent Developments
14.1.2.4. Strategy
14.1.3. Johnson & Johnson
14.1.3.1. Overview (HQ, Employee Strength, Business Segments)
14.1.3.2. Financials
14.1.3.3. Recent Developments
14.1.3.4. Strategy
14.1.4. Novartis AG
14.1.4.1. Overview (HQ, Employee Strength, Business Segments)
14.1.4.2. Financials
14.1.4.3. Recent Developments
14.1.4.4. Strategy
14.1.5. Bristol-Myers Squibb Company
14.1.5.1. Overview (HQ, Employee Strength, Business Segments)
14.1.5.2. Financials
14.1.5.3. Recent Developments
14.1.5.4. Strategy
14.1.6. Abbott
14.1.6.1. Overview (HQ, Employee Strength, Business Segments)
14.1.6.2. Financials
14.1.6.3. Recent Developments
14.1.6.4. Strategy
14.1.7. Bayer AG
14.1.7.1. Overview (HQ, Employee Strength, Business Segments)
14.1.7.2. Financials
14.1.7.3. Recent Developments
14.1.7.4. Strategy
14.1.8. Koninklijke Philips N.V
14.1.8.1. Overview (HQ, Employee Strength, Business Segments)
14.1.8.2. Financials
14.1.8.3. Recent Developments
14.1.8.4. Strategy
14.1.9. GE Healthcare
14.1.9.1. Overview (HQ, Employee Strength, Business Segments)
14.1.9.2. Financials
14.1.9.3. Recent Developments
14.1.9.4. Strategy
14.1.10. Physio-Control, Inc. (Stryker)
14.1.10.1. Overview (HQ, Employee Strength, Business Segments)
14.1.10.2. Financials
14.1.10.3. Recent Developments
14.1.10.4. Strategy
14.1.11. Boston Scientific Corporation
14.1.11.1. Overview (HQ, Employee Strength, Business Segments)
14.1.11.2. Financials
14.1.11.3. Recent Developments
14.1.11.4. Strategy
14.1.12. Cardiac Science Corporation (Aurora Capital Group)
14.1.12.1. Overview (HQ, Employee Strength, Business Segments)
14.1.12.2. Financials
14.1.12.3. Recent Developments
14.1.12.4. Strategy
14.1.13. Shenzhen Mindray Bio-Medical Electronics Co., Ltd
14.1.13.1. Overview (HQ, Employee Strength, Business Segments)
14.1.13.2. Financials
14.1.13.3. Recent Developments
14.1.13.4. Strategy
TABLE 1 Prevalence Rate of Cardiac Arrest In Key Countries
TABLE 2 Promising Treatments in Clinical Development: Cardiac Arrest, by Phase 2 Drugs
TABLE 3 Promising Treatments in Clinical Development: Cardiac Arrest, by Phase 3 and Phase 4 Drugs
TABLE 4 Annual cost of prehospital equipment per patient used to treat OHCA (Out- of Hospital Cardiac Arrest)
TABLE 5 Cost incurred to cardiac arrest patients
TABLE 6 Key Merger and Acquisition (1/2)
TABLE 7 Key Merger and Acquisition (2/2)
TABLE 8 Percent of Heart Failure Trials, by Phase and Location
TABLE 9 Percent of Heart Failure Trials, by Phase and Companies
TABLE 10 Pipeline Analysis for Cardiovascular Disorders Therapeutics (1/5)
TABLE 11 Pipeline Analysis for Cardiovascular Disorders Therapeutics (2/5)
TABLE 12 Pipeline Analysis for Cardiovascular Disorders Therapeutics (3/5)
TABLE 13 Pipeline Analysis for Cardiovascular Disorders Therapeutics (4/5)
TABLE 14 Pipeline Analysis for Cardiovascular Disorders Therapeutics (5/5)
TABLE 15 Global Cardiac Arrest Treatment Market Size (US$ Mn) Forecast, by Treatment, 2017–2027
TABLE 16 Global Cardiac Arrest Treatment Market Size (US$ Mn) Forecast, by Drugs, 2017–2027
TABLE 17 Global Cardiac Arrest Treatment Market Size (US$ Mn) Forecast, by Medical Devices, 2017–2027
TABLE 18 Global Cardiac Arrest Treatment Market Size (US$ Mn) Forecast, by Sales Channel, 2017–2027
TABLE 19 Global Cardiac Arrest Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2027
TABLE 20 North America Cardiac Arrest Treatment Market Value (US$ Mn) Forecast, by Country, 2017–2027
TABLE 21 North America Cardiac Arrest Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2027
TABLE 22 North America Cardiac Arrest Treatment Market Value (US$ Mn) Forecast, by Drugs, 2017–2027
TABLE 23 North America Cardiac Arrest Treatment Market Value (US$ Mn) Forecast, by Medical Devices, 2017–2027
TABLE 24 North America Cardiac Arrest Treatment Market Value (US$ Mn) Forecast, by Sales Channel, 2017–2027
TABLE 25 Europe Cardiac Arrest Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
TABLE 26 Europe Cardiac Arrest Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2027
TABLE 27 Europe Cardiac Arrest Treatment Market Value (US$ Mn) Forecast, by Drugs, 2017–2027
TABLE 28 Europe Cardiac Arrest Treatment Market Value (US$ Mn) Forecast, by Medical Devices, 2017–2027
TABLE 29 Europe Cardiac Arrest Treatment Market Value (US$ Mn) Forecast, by Sales Channel, 2017–2027
TABLE 30 Asia Pacific Cardiac Arrest Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
TABLE 31 Asia Pacific Cardiac Arrest Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2027
TABLE 32 Asia Pacific Cardiac Arrest Treatment Market Value (US$ Mn) Forecast, by Drugs, 2017–2027
TABLE 33 Asia Pacific Cardiac Arrest Treatment Market Value (US$ Mn) Forecast, by Medical Devices, 2017–2027
TABLE 34 Asia Pacific Cardiac Arrest Treatment Market Value (US$ Mn) Forecast, by Sales Channel, 2017–2027
TABLE 35 Latin America Cardiac Arrest Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
TABLE 36 Latin America Cardiac Arrest Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2027
TABLE 37 Latin America Cardiac Arrest Treatment Market Value (US$ Mn) Forecast, by Drugs, 2017–2027
TABLE 38 Latin America Cardiac Arrest Treatment Market Value (US$ Mn) Forecast, by Medical Devices, 2017–2027
TABLE 39 Latin America Cardiac Arrest Treatment Market Value (US$ Mn) Forecast, by Sales Channel, 2017–2027
TABLE 40 Middle East & Africa Cardiac Arrest Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
TABLE 41 Middle East & Africa Cardiac Arrest Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2027
TABLE 42 Middle East & Africa Cardiac Arrest Treatment Market Value (US$ Mn) Forecast, by Drugs, 2017–2027
TABLE 43 Middle East & Africa Cardiac Arrest Treatment Market Value (US$ Mn) Forecast, by Medical Devices, 2017–2027
TABLE 44 Middle East & Africa Cardiac Arrest Treatment Market Value (US$ Mn) Forecast, by Sales Channel, 2017–2027